Frontier | FDA approved new gene editing therapies for the treatment of OTC deficiency in clinical practice; LSTA1, a new drug for the treatment of osteosarcoma, has been recognized as an orphan drug

01 FDA approved new gene editing therapy for the treatment of OTC deficiency in clinical practice On April 4, 2024, the FDA approved the clinical study approval application for ECUR-506 for the treatment of neonatal patients with ornithine aminotransferase (OTC) deficiency. OTC deficiency, also known as hyperammonemia type II, is an X-linked genetic disease caused…

Read More

Avantium stops its bio based polyol business and focuses on FDCA and PEF!

Biobased Energy and Materials learned that recently, Dutch green chemical company Avantium announced that it will fully focus on the production and sales of FCDA and PEF technologies. It will stop investing in Ray technology for producing plantMEG (plant-based ethylene glycol) and plantMPG (plant-based propylene glycol) until suitable strategic equity partners are found. FDCA (Furanedicarboxylic…

Read More

EU funded project to develop 24 bio based products using enzymes and strains from olive leaves

At present, Spain has a large amount of biomass (olive leaves) that has not been fully utilized, but discarded olive leaves are rich in valuable bioactive compounds, giving them the opportunity to become a potential carbon source for various industries. The number of underutilized olive leaves is astonishing. Olive trees planted for the production of…

Read More

Ginkgo announces Q3 financial report: $55 million recorded, establishing new partnerships with Pfizer and Google

On November 8, 2023 Eastern Time, synthetic biology company Ginkgo Bioworks (NYSE: DNA, hereinafter referred to as Ginkgo) released its financial performance report for the third quarter of 2023. (Source: Company website)   According to the company’s official website, Ginkgo’s total revenue in the third quarter of 2023 was $55 million, down from $66 million…

Read More